FDA panel backs Emmaus' sickle cell therapy

FDA's Oncologic Drugs Advisory Committee voted 10-3 in favor of approval of Endari L-glutamine from Emmaus Life Sciences Inc. (Torrance, Calif.) to treat sickle cell disease

Read the full 264 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE